SLC25A25-AS1 over-expression could be predicted the dismal prognosis and was related to the immune microenvironment in prostate cancer

Ying-Ying Zhao; Qian-Ming Xiang; Jia-Li Chen; Li Zhang; Wei-Long Zheng; Di Ke; Rong-Shu Shi; Kong-Wu Yang

doi:10.3389/fonc.2022.990247

SLC25A25-AS1 over-expression could be predicted the dismal prognosis and was related to the immune microenvironment in prostate cancer

Front Oncol. 2022 Oct 20:12:990247. doi: 10.3389/fonc.2022.990247. eCollection 2022.

Authors

Ying-Ying Zhao^{1

2}, Qian-Ming Xiang³, Jia-Li Chen², Li Zhang², Wei-Long Zheng², Di Ke¹, Rong-Shu Shi¹, Kong-Wu Yang¹

Affiliations

¹ Department of Radiology, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
² Department of Radiology, Fuqing City Hospital Affiliated to Fujian Medical University, Fuqing, China.
³ Department of General Surgery, The First Affiliated Hospital of Kunming Medical University, Kunming, China.

Abstract

It has been established that long-chain coding RNA (lncRNA) SLC25A25-AS1 is associated with cancer progression. However, the roles and mechanisms of SLC25A25-AS1 in prostate cancer (PC) have not been reported in the literature. The present study explored the relationship between SLC25A25-AS1 expression and PC progression via comprehensive analysis. The pan-cancer expression of SLC25A25-AS1 was identified using data from The Cancer Genome Atlas (TCGA) database and tissue specimens from our hospital. The expression levels of SLC25A25-AS1 in various subgroups based on the clinical features were identified. The prognostic value of SLC25A25-AS1 and SLC25A25-AS1 co-expressed lncRNAs in PC patients was assessed by survival analysis and ROC analysis, and prognosis-related risk models of SLC25A25-AS1 were constructed. The relationship between SLC25A25-AS1 and the PC immune microenvironment was investigated using correlation analysis. SLC25A25-AS1 expression in PC was significantly increased and correlated with the T stage, clinical stage, Gleason score (GS), and dismal prognosis. SLC25A25-AS1 overexpression exhibited good performance in evaluating the prognosis of PC patients. The area under the curves (AUCs) of the 1-, 3-, and 5-year overall survival (OS) for SLC25A25-AS1 was 1, 0.876, and 0.749. Moreover, the AUCs for the 1-, 3-, and 5-year progress free interval (PFI) for SLC25A25-AS1 were 0.731, 0.701, and 0.718. SLC25A25-AS1 overexpression correlated with the infiltration of CD8 T cells, interstitial dendritic cells (IDC), macrophages and other cells. AC020558.2, ZNF32-AS2, AP4B1-AS1, AL355488.1, AC109460.3, SNHG1, C3orf35, LMNTD2-AS1, and AL365330.1 were significantly associated with SLC25A25-AS1 expression, and short OS and PFI in PC patients. The risk models of the SLC25A25-AS1-related lncRNAs were associated with a dismal prognosis in PC. Overall, SLC25A25-AS1 expression was increased in PC and related to the prognosis and PC immune microenvironment. The risk model of SLC25A25-AS1 have huge prospect for application as prognostic tools in PC.

Keywords: SLC25A25-AS1; biomarker; immune microenvironment; prognosis; prostate cancer.